MedTrace Logo

Safety and Efficacy of Albiglutide in Type 2 Diabetes

NCT00849056 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 310

Last updated 2017-01-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety, tolerability and efficacy of albiglutide in the treatment of type 2 diabetes.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

BIOLOGICAL

albiglutide

albiglutide weekly subcutaneous injection

DRUG

placebo

placebo weekly subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-11-30
Completion
2013-01-31

Countries

  • United States
  • India
  • Peru
  • South Africa
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00849056 on ClinicalTrials.gov